Activation of Latent Oncogenic Viruses as a Form of Targeted Cancer Therapy
Time: 12:00 pm
day: Day Two
- Outlining the Epstein-Barr virus (EBV), a ubiquitous lymphotropic herpesvirus, associated with a heterogenous group of malignancies.
- Demonstrating how Nanatinostat induces expression of the EBV protein kinase, BGLF4, which activates the antiviral ganciclovir via phosphorylation to block DNA synthesis and trigger apoptosis.
- Discussing our phase 1b/2 clinical data which demonstrated promising efficacy and safety in patients with various subtypes of relapsed/refractory Epstein-Barr virus-positive lymphoma